Why was this work needed?
Angiotensin receptor blockers are drugs that are commonly used to treat heart failure, high blood pressure and diabetic nephropathy (kidney damage). However, there had been some concerns that they might also increase the risk of cancer.
This study used GP data to compare the cancer rates of people taking angiotensin receptor blockers with the cancer rates among people taking ACE inhibitors, which is not thought to raise cancer risk.
What were the benefits?
The researchers showed that there was no significant difference in cancer rates between the two groups and therefore concluded that angiotensin receptor blockers do not increase the risk of cancer. This is reassuring and important information for doctors and patients alike.
What type of data was involved?
This study used the Clinical Practice Research Datalink (CPRD).
What was the legal basis for accessing the data?
All data was de-personalised before being used by the researchers.
Who funded and collaborated on this work?
The funding for this research came from a post-doctoral fellowship from the National Institute for Health Research (NIHR).
Where can I go for more information?
- Page updated: 31 August 2017
- Print page